Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611

Fineline Cube Jan 30, 2026
Company Deals

Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21

Fineline Cube Jan 30, 2026
Company Deals

CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio

Fineline Cube Jan 30, 2026
Company Deals

Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China

Fineline Cube Jan 29, 2026
Company Deals

Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform

Fineline Cube Jan 29, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026
Company Drug

China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo

Fineline Cube Jan 30, 2026
Company Drug

Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia

Fineline Cube Jan 30, 2026
Company Drug

CanSino Biologics Initiates Phase I/II Study for CS-2036 Polio Vaccine with Gates Foundation Support

Fineline Cube Dec 23, 2024

CanSino Biologics (SHA: 688185, HKG: 6185) has announced the initiation of a Phase I/II study...

Company Drug

Innovent Biologics’ Taletrectinib Wins NMPA Approval for ROS1+ NSCLC Treatment

Fineline Cube Dec 23, 2024

China-based Innovent Biologics, Inc. (HKG: 1801) has announced receiving marketing approval from the National Medical...

Company Medical Device

MicroPort Scientific Corp. Receives NMPA Approval for FireRaptor Coronary Atherectomy System

Fineline Cube Dec 23, 2024

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced receiving marketing approval from...

Company

Biopharma Company TransThera Sciences (Nanjing) Gets Green Light for HK IPO

Fineline Cube Dec 22, 2024

On December 20, 2024, the China Securities Regulatory Commission confirmed the listing filing for TransThera...

Company Drug

YolTech Therapeutics’ YOLT-201 Advances in ATTR Treatment Clinical Trial

Fineline Cube Dec 21, 2024

Shanghai, China, December 21, 2024 — YolTech Therapeutics today announced that its proprietary in vivo...

Company Deals

Wuhan Weike Medical Technology Secures Series C Funding to Boost Cardiovascular Innovation

Fineline Cube Dec 21, 2024

Wuhan Weike Medical Technology Co., Ltd., known as “Weike Medical,” has officially announced the successful...

Company Deals

Sumitomo Pharma Expands Collaboration with Shanghai Pharmaceuticals for Prescription Drug Co-Marketing

Fineline Cube Dec 20, 2024

Japan-based Sumitomo Pharma Co., Ltd (TYO: 4506) has announced an expanded Contract Sales Organization (CSO)...

Company Medical Device

Boston Scientific’s Next-Gen IVUS System AVVIGO+ Approved by China’s NMPA for Coronary Disease Use

Fineline Cube Dec 20, 2024

US-based Boston Scientific Corporation (NYSE: BSX) has announced that China’s National Medical Products Administration (NMPA)...

Company Deals

Guardant Health and Boehringer Ingelheim Join Forces to Develop Guardant360 CDx for Zongertinib Companion Diagnostic

Fineline Cube Dec 20, 2024

US-based precision oncology specialist Guardant Health, Inc. (NASDAQ: GH) has entered into an agreement with...

Company Drug

Roche’s Prasinezumab Shows Promise in Phase IIb PADOVA Study for Early-Stage Parkinson’s Disease

Fineline Cube Dec 20, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has published results from the Phase IIb PADOVA study...

Company Deals

Hainan Boao Lecheng and Sanofi Partner with Paris-Saclay Cancer Cluster for Advanced Cancer Treatments

Fineline Cube Dec 20, 2024

The Hainan Boao Lecheng International Medical Tourism Pilot Zone, in collaboration with France’s major Sanofi’s...

Company Drug

Sichuan Kelun-Biotech Launches Sacituzumab Tirumotecan for Triple Negative Breast Cancer in China

Fineline Cube Dec 20, 2024

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced the commercial launch of its...

Company Deals

WuXi Biologics Enters Licensing Deal with Hangzhou DAC and Aadi Bio for Preclinical ADC Portfolio

Fineline Cube Dec 20, 2024

China-based Contract Research and Development Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a strategic...

Company Deals

MGI Tech Co., Ltd Partners with Sabin Group to Enhance Genetic Sequencing in Brazil

Fineline Cube Dec 20, 2024

China-based gene sequencing specialist MGI Tech Co., Ltd (SHA: 688114) has entered into a strategic...

Company Deals

Astellas Pharma Inks Licensing Deal with Sangamo Therapeutics for Neurological AV Capsid STAC-BBB

Fineline Cube Dec 20, 2024

Japan-based Astellas Pharma Inc. (TYO: 4503) has revealed a strategic licensing agreement with US-based Sangamo...

Company Deals

BioArctic AB Secures Global Rights to PyroGlu-Aβ Antibody Program in BMS Deal

Fineline Cube Dec 20, 2024

Sweden-based BioArctic AB (OTCMKTS: BRCTF) has announced a significant licensing agreement with US pharmaceutical giant...

Company Deals

Fangzhou Inc. Partners with BMS to Innovate Digital Medicine Platform

Fineline Cube Dec 20, 2024

China-based Internet healthcare solutions provider Fangzhou Inc. (HKG: 6086) has entered into a partnership with...

Company Digital

Sanofi and Corxel Pharmaceuticals Partner for Aficamten in Greater China Rights

Fineline Cube Dec 20, 2024

Global healthcare leader Sanofi (NASDAQ: SNY) and China-based Corxel Pharmaceuticals (CORXEL), formerly known as Ji...

Company Deals

HOB Biotech Group Corp. Acquired by Sino Biopharmaceutical Ltd for IVD Synergies

Fineline Cube Dec 20, 2024

China-based in vitro diagnostic (IVD) reagents specialist HOB Biotech Group Corp., Ltd (SHA: 688656) has...

Company Drug

Joincare Pharmaceutical’s JKN2403 Gains NMPA Approval for COPD Clinical Trials

Fineline Cube Dec 20, 2024

China-based Jo2006incare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) is set to advance its Category...

Posts pagination

1 … 192 193 194 … 617

Recent updates

  • China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo
  • Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia
  • CSPC’s SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials
  • AstraZeneca Commits $14.4B China Investment in Cell Therapy Push
  • Ascletis ASC40 Phase III Success in Acne Vulgaris
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo

Company Drug

Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia

Company Drug

CSPC’s SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials

Company

AstraZeneca Commits $14.4B China Investment in Cell Therapy Push

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.